登录 | 注册    关注公众号  
搜索

CEACAM-8信息

英文名称:Non specific cross-reacting antigen 95
中文名称:非特异性交叉反应抗原95
靶点别称:Non-specific cross-reacting antigen NCA-95,CGM6,Carcinoembryonic Antigen Gene Family Member 6,CD66b Antigen,NCA-95,CD67,Carcinoembryonic antigen CGM6,CD66b,CEACAM8,Carcinoembryonic Antigen Related Cell Adhesion Molecule 8,Carcinoembryonic Antigen-Related Cell Adhesion Molecule 8,CD67 Antigen,CEA Cell Adhesion Molecule 8
上市药物数量:1
临床药物数量:1
最高研发阶段:批准上市

CEACAM-8产品列表

 
评论(0)
 

CEACAM-8 分子别名

CEACAM8,CD66b,CD67,CGM6,NCA-95

CEACAM-8 分子背景

Carcinoembryonic antigen-related cell adhesion molecule 8 (CEACAM8) is also known as CD66b (Cluster of Differentiation 66b), CD66b, CD67, CGM6, NCA-95, and is one of seven human CEACAM family members within the immunoglobulin superfamily. CEACAM family members are a set of widely expressed proteins involved in several biological functions, including cell adhesion, migration, signal transduction, and the regulation of gene expression. Abnormal overexpression and downregulation of some CEACAMs have been described in tumor cells. In humans, CEACAMs include type I transmembrane proteins (CEACAM1, CEACAM3, and CEACAM4) and GPI-linked molecules (CEACAM5 through CEACAM8). There is no human CEACAM2. CEACAM8 is a single chain, two Ig-like C2-type (immunoglobulin-like) domains and one Ig-like V-type (immunoglobulin-like) domain. It is an activation marker for human granulocytes.

CEACAM-8 前沿进展

CEACAM-8上市药物信息

英文名称 中文名称 研发代码 研发阶段 公司 最早商品名 最早批准国家 最早适应症 最早批准公司 最早批准日期 适应症 临床试验
Besilesomab BW-250-183; 99Tcm-BW250-183; TLX-66-CDx; TLX66-CDx 批准上市 Cis Bio International Sa Scintimun EU 骨髓炎 Cis Bio International Sa 2010-01-11 骨髓炎 详情

CEACAM-8临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
90Y-DTPA-besilesomab TLX-66 临床二期 Telix Pharmaceuticals Ltd 多发性骨髓瘤, 浆细胞肿瘤 详情

消息提示

请输入您的联系方式,再点击提交!

确定